Q-omics provides the consensus-scored FMO6P profile across patient tissues and cancer cell-line models. FMO6P expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, FMO6P is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, FMO6P RNA expression shows 16,337 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight BLCA, KIRC, and PDAC as cancer lineages where FMO6P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FMO6P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FMO6P survival associations across molecular data types. FMO6P RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FMO6P RNA expression–survival associations across cancer types. High FMO6P expression shows unfavorable associations in BLCA, COAD and READ, but favorable associations in LUSC, SKCM and UCEC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for FMO6P RNA expression.
This table summarizes FMO6P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for FMO6P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FMO6P shows lower tumor expression in BRCA, STAD and LUAD and higher tumor expression in KIRC, LUSC and UCEC. The KIRC box plot shows higher FMO6P RNA expression in tumor versus normal tissue (log2 FC = +0.057, t-test p < 0.001).
This table shows molecular features associated with FMO6P in patient tissues and cancer cell lines. In patient samples, FMO6P shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, FMO6P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and CNS.
